The U.S. Supreme Court on Monday issued a temporary order restoring broad access to the abortion medication mifepristone, blocking a lower court decision that would have imposed stricter distribution requirements. Justice Samuel Alito signed the order, which allows the drug to continue being provided through pharmacies, telehealth services, and the mail without requiring an in-person physician visit.
The relaxed rules had been implemented during the Biden administration and had been in effect for several years. Medication abortions, typically involving mifepristone followed by misoprostol, now account for the majority of abortions performed in the United States. The availability of the pill has played a significant role in maintaining access following the Supreme Court’s 2022 decision overturning Roe v. Wade.
The case stems from a challenge by the state of Louisiana, which argued that the FDA failed to adequately consider safety risks when it removed the in-person dispensing requirement. Louisiana officials contended that the drug should only be distributed in clinical settings to protect patients from rare but serious complications such as hemorrhaging and infection.
Last week, the U.S. Court of Appeals for the Fifth Circuit temporarily sided with Louisiana in a unanimous ruling, questioning the scientific basis for the FDA’s regulatory changes. Manufacturers of mifepristone filed emergency appeals, arguing that the restrictions would severely limit access, especially in states with abortion bans or limited clinic availability.
The Supreme Court’s temporary stay will remain in place while the parties submit additional briefing and the Court considers the matter more fully. The order does not constitute a final decision on the merits of the case.
The development reflects ongoing national divisions over abortion policy more than three years after the Dobbs decision returned regulatory authority to the states. While some states have enacted strict limits or bans, others have taken steps to expand access to medication abortion via telehealth and mail delivery.
Legal observers note that the case highlights tensions between federal regulatory authority and state efforts to enforce abortion restrictions. Louisiana’s lawsuit contended that the FDA’s actions undermined the state’s abortion ban and exposed patients to unnecessary risks. The Biden administration had defended the rule, citing extensive clinical data showing serious adverse events occur in less than 1 percent of cases.
The companies that produce mifepristone — Danco Laboratories (brand-name Mifeprex) and GenBioPro (generic version) — intervened to support continued access, warning that new restrictions would disrupt care for patients who rely on medication abortion. Some Democrat-led states have enacted laws shielding providers who prescribe the drug via telehealth to out-of-state patients.
The Supreme Court’s action is procedural and temporary. Both sides will now file responses as the Court evaluates whether to grant a full hearing or allow the Fifth Circuit’s restrictions to take effect. The outcome could have significant implications for medication abortion access nationwide, particularly in states where clinics are scarce or outright bans are in place.
